Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 952128, 8 pages
Review Article

Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy

1Roger Williams Medical Center Brain Tumor Laboratory, 825 Chalkstone Avenue, Prior 222, Providence, RI 02908, USA
2Department of Neurosurgery, Boston University School of Medicine, Boston, MA 02118, USA
3University of Illinois College of Medicine, Urbana-Champaign, IL 61801, USA

Received 3 April 2014; Accepted 5 August 2014; Published 27 August 2014

Academic Editor: Gustavo Pradilla

Copyright © 2014 Sadhak Sengupta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Glioblastoma (GBM) is the most lethal primary brain tumor, and despite several refinements in its multimodal management, generally has very poor prognosis. Targeted immunotherapy is an emerging field of research that shows great promise in the treatment of GBM. One of the most extensively studied targets is the interleukin-13 receptor alpha chain variant 2 (IL13Rα2). Its selective expression on GBM, discovered almost two decades ago, has been a target for therapy ever since. Immunotherapeutic strategies have been developed targeting IL13Rα2, including monoclonal antibodies as well as cell-based strategies such as IL13Rα2-pulsed dendritic cells and IL13Rα2-targeted chimeric antigen receptor-expressing T cells. Advanced therapeutic development has led to the completion of several clinical trials with promising outcomes. In this review, we will discuss the recent advances in the IL13Rα2-targeted immunotherapy and evaluate the most promising strategy for targeted GBM immunotherapy.